Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Chiarle

Showing results (51-60 of 156) with videos related to

Pageof 16
Sort By:
Blood|January 10, 2016
Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic miceRamesh Choudhari, Valerio Giacomo Minero, Matteo Menotti, et al.
Cell Reports|December 3, 2014
Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technologyRafael B Blasco, Elif Karaca, Chiara Ambrogio, et al.
Advances in Immunology|August 24, 2010
The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancersYu Zhang, Monica Gostissa, Dominic G Hildebrand, et al.
Cancer Research|November 1, 2008
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activationChiara Ambrogio, Claudia Voena, Andrea D Manazza, et al.
Blood Advances|January 28, 2022
Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newbornRahela Aziz-Bose, Franziska Wachter, Roberto Chiarle, et al.
Nature Immunology|March 17, 2004
The STAT3 isoforms alpha and beta have unique and specific functionsDiego Maritano, Michelle L Sugrue, Silvia Tininini, et al.
Molecular Carcinogenesis|December 23, 2009
Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogeneIsaia Barbieri, Elena Quaglino, Diego Maritano, et al.
Blood Advances|August 1, 2022
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomasGiovanni Rindone, Andrea Aroldi, Elisa Bossi, et al.
Oncotarget|April 21, 2017
Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridizationLaura Annaratone, Michele Simonetti, Erik Wernersson, et al.
Nature Medicine|May 17, 2005
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetRoberto Chiarle, William J Simmons, Honjying Cai, et al.
Pageof 16

Showing results (51-60 of 156) with videos related to

Sort By:
Pageof 16
Blood|January 10, 2016
Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic miceRamesh Choudhari, Valerio Giacomo Minero, Matteo Menotti, et al.
Cell Reports|December 3, 2014
Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technologyRafael B Blasco, Elif Karaca, Chiara Ambrogio, et al.
Advances in Immunology|August 24, 2010
The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancersYu Zhang, Monica Gostissa, Dominic G Hildebrand, et al.
Cancer Research|November 1, 2008
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activationChiara Ambrogio, Claudia Voena, Andrea D Manazza, et al.
Blood Advances|January 28, 2022
Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newbornRahela Aziz-Bose, Franziska Wachter, Roberto Chiarle, et al.
Nature Immunology|March 17, 2004
The STAT3 isoforms alpha and beta have unique and specific functionsDiego Maritano, Michelle L Sugrue, Silvia Tininini, et al.
Molecular Carcinogenesis|December 23, 2009
Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogeneIsaia Barbieri, Elena Quaglino, Diego Maritano, et al.
Blood Advances|August 1, 2022
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomasGiovanni Rindone, Andrea Aroldi, Elisa Bossi, et al.
Oncotarget|April 21, 2017
Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridizationLaura Annaratone, Michele Simonetti, Erik Wernersson, et al.
Nature Medicine|May 17, 2005
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetRoberto Chiarle, William J Simmons, Honjying Cai, et al.
Pageof 16